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We determined the crystal structure of the motor domain of human non-muscle myosin 2B (NM-2B)
in a nucleotide-free state and at a resolution of 2.8 Å. The structure shows themotor domain with an
open active site and the large cleft that divides the 50kDa domain in a closed state. Compared to
other rigor-like myosin motor domain structures, our structure shows subtle but signiﬁcant confor-
mational changes in regions important for actin binding and mechanochemical coupling. Moreover,
our crystal structure helps to rationalize the impact of myosin, heavy chain 9 (MYH9)-related disease
mutations Arg709Cys and Arg709His on the kinetic and functional properties of NM-2B and of the
closely related non-muscle myosin 2A (NM-2A).
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Myosins are molecular motors that use the energy stored in ATP
to power directed movement along actin ﬁlaments for various
processes like muscle contraction, cell motility and vesicle trans-
port [1,2]. The more than 38 different myosins in man are subdi-
vided into different classes, based on sequence comparison [3].
The conventional cytoplasmic class 2 non-muscle myosin-2s
(NM-2s) are hexameric and composed of two heavy chains and a
pair of essential and regulatory light chain [4]. These double-
headed myosins generate force for processes such as cytokinesis,
cell migration and cell shape alterations [4]. In mammals, the three
NM-2 heavy chain homologs NM-2A, -2B and -2C are encoded by
the genes MYH9, MYH10 and MYH14, respectively. A high degree
of sequence identity suggests a close evolutionary relationship
arising from gene duplication. The NM-2A and 2B heavy chains
share 80% sequence identity and 90% similarity. The NM-2B and
2C heavy chains are more divergent with 68% identity and 80%
similarity, due to larger differences between their tail domains.
NM-2B has four alternatively spliced isoforms NM-2B0, B1a, B1b
and B2, which differ by insertions into loop 1 and loop 2 [5]. The
loop 1-inserted isoforms B1a and B1b are speciﬁcally produced inneuronal cells [6]. Several mutations in MYH9, the gene encoding
the NM-2A heavy chain isoform, lead to changes within the motor
domain that have been associated with congenital macrothrombo-
cytopenia, cytoplasmic inclusion bodies in granulocytes, sensori-
neural hearing loss and renal failure. These symptoms have
previously been assigned to autosomal dominant May–Hegglin
anomaly [7,8] and Sebastian, Fechtner and Epstein syndromes.
More recently, they have been summarized under the common
term MYH9-related disease (MYH9-RD) [9]. Sequence identity and
similarity between the NM-2A and 2B motor domains are 85%
and 92%, respectively. Regions containing MYH9-related disease
mutations are identical in sequence between these two isoforms
(Fig. S1). Thus, the structure of the NM-2B motor forms a good
basis for deducing effects of disease-related mutations in the
NM-2A motor domain.
Here, we report the expression, puriﬁcation, crystallization and
crystal structure of the human NM-2B0 motor domain in the
nucleotide-free state at a resolution of 2.8 Å. The open active site
and closed actin binding cleft classify this structure as rigor-like.
The structure is overall similar to the motor domains of nucleo-
tide-free chicken myosin-5A (PDB ID: 1OE9) and Dd myosin-2
(PDB ID: 2AKA) with rmsd values of 0.98 Å and 1.752 Å, respec-
tively. Regions important for actin binding and mechanochemical
coupling exhibit subtle but signiﬁcant differences that appear to
be related to distinct motor properties. Moreover, we provide
insights into the structural perturbations that are caused by muta-
tions affecting position R709, which are implicated in MYH9-RD.
Table 1
Data collection and structure reﬁnement statistics.
Data statistics
Beamline P14 @ PETRA III, DESY (Hamburg, Germany)
Space group P 1 21 1
Unit cell parameters
a, b, c (Å) 65.85, 157.87, 143.48
a, b, c () 90.0, 94.213, 90.0
Wavelength (Å) 0.9763
Resolution (Å) 30.0–2.84 (3.10–2.84)
CC(1/2) 99.5 (60.2)
Rmerge 0.104 (0.88)
I/rI 7.21 (1.06)
Wilson B factor (Å2) 68.6
Completeness (%) 95.1 (96.4)
No. observations 143589 (33744)
No. unique reﬂections 65526 (15282)
Multiplicity 2.2 (2.2)
Reﬁnement
Resolution (Å) 30.0–2.84
No. reﬂections total 65449
Rwork/Rfree (%) 25.33/28.81
Average B factor (Å2) 82.1
R.m.s. deviations
Bond angles () 0.0021
Bond lengths (Å) 0.718
Ramachandran plot
Favored (%) 96.26
Additionally allowed (%) 3.69
Outliers (%) 0.05
MolProbity score 1.57
Values in parentheses are for the highest resolution shell.
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to a network of interactions that connects the SH1 helix with the
relay region. Modeling of the pre-power stroke state predicts that
R709 is disconnected from the network in states with low actin
afﬁnity.Fig. 1. (A) 3D crystals of NM-2B; the scale bar indicates 100 lm. (B) Two molecules of
whereas molecule B is light blue. The N-terminus is colored in orange. (C) Structural align
near identity in the motor domain. The pink arrows highlight differences in the conform2. Materials and methods
2.1. Cloning, expression and puriﬁcation of human NM-2B
An expression construct was generated encoding the motor
domain of human NM-2B0 (residues 1–782) fused with two Dicty-
ostelium discoideum a-actinin repeats, and an octahistidine-tag.
The recombinant plasmid was transformed into E. coli DH10Bac
competent cells (Invitrogen) for transposition into the bacmid.
Sf9 cells were transfected with recombinant bacmid using FuGENE
HD transfection reagent (Promega, Fitchburg, WI) followed by
5 days of growth at 27 C. After several rounds of virus ampliﬁca-
tion, recombinant protein was expressed by infecting Sf9 cells for
3 days at 27 C, shaking at 90 rpm in suspension culture. Cell
pellets were either used directly for protein puriﬁcation or ﬂash-
frozen in liquid nitrogen and stored at -80 C. Sf9 cells were sus-
pended in lysis buffer (50 mM HEPES pH 7.5, 200 mM NaCl,
10 mM b-mercaptethanol, 4 mM MgCl2, 4 mM ATP, 1 mM EGTA,
0.5% Triton X-100 and protease inhibitor cocktail) and sonicated
for 4  60 s. The lysate was centrifuged at 100000g for 1 h at
4 C and the supernatant was incubated for 1 h with Ni2+ afﬁnity
column equilibrated with lysis buffer. The column was washed
with lysis buffer and wash buffer (25 mM HEPES, pH 7.3,
200 mM NaCl, 0.5 mM EGTA, 3 mM MgCl2, 65 mM imidazole).
The protein was eluted with buffer E (25 mM HEPES pH 7.3,
200 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1 mM DTT, and 200 mM
imidazole). The elution fractions were dialyzed overnight against
dialysis buffer (25 mM HEPES pH 7.3, 200 mM NaCl, 1 mM EGTA,
1 mM EDTA, 1 mM DTT, and 3% trehalose). Dialyzed protein was
applied to a Superdex 200 pg 16/60 gel ﬁltration column (GE
Healthcare) previously equilibrated with dialysis buffer. Puriﬁed
protein was either directly used for crystallization or supple-
mented with trehalose to a ﬁnal concentration of 10% (w/v),
ﬂash-frozen in liquid nitrogen, and stored at 80 C.NM-2B are located in the asymmetric unit. Molecule A of NM-2B is colored blue,
ment of the two molecules in the asymmetric unit shows high similarity overall and
ations of molecule A and B.
4756 S. Münnich et al. / FEBS Letters 588 (2014) 4754–47602.2. Crystallization, data collection and structure determination
Human NM-2B0 (residues 1-782 fused to an artiﬁcial lever arm
of a-actinin repeats) was crystallized at 6.8 mg/mL. Initial crystal
screening was performed by mixing 0.2 lL of protein with 0.2 lL
of screening solution using a Phoenix crystallization robot (Art
Robbins Instruments, Sunnyvale, USA) in a vapor-diffusion set-up
at 18 C. Commercially available screens included JCSG++ and
PACT++ (Jena Bioscience, Jena, Germany). Nucleotide-free NM-2B
crystallized in 10% (w/v) PEG 6000 and 0.1 M HEPES pH 7.0.
Plate-shaped crystals appeared overnight and grew to ﬁnal dimen-
sions of 20  100  200 lm. Crystals were cryo-protected with
15% (w/v) PEG 6000, 0.1 M HEPES pH 7.0 and 20% (v/v) glycerolFig. 2. (A) The N-terminus that is located in a cavity between the two molecules of
the asymmetric unit is shown in orange. (B) The N-termini of different nucleotide-
free myosin structures (myosin-1b in purple and Dd myosin-2 in green) are
compared. The box represents a close-up view of the N-terminal residues of
different myosins.and ﬂash-frozen in liquid nitrogen. A complete data set was
collected at 100 K at the EMBL beam line P14 at PETRA III, DESY,
Hamburg to a resolution of 2.8 Å. Reﬂections were indexed, inte-
grated and scaled in XDS [10]. The structure was determined with
molecular replacement using PHENIX.Phaser, [11] with the nucle-
otide-free structure of myosin-5A as search model (PDB ID: 1OE9,
[12]). The initial molecular replacement solution was automati-
cally and iteratively rebuilt and reﬁned in PHENIX.Autobuild and
PHENIX.Reﬁne [13] and manually built and inspected in Coot
[14]. Data collection and reﬁnement statistics are summarized in
Table 1. All structural ﬁgures were generated with PyMOL (The
PyMOL Molecular Graphics System, Version 1.5.0.4, Schrödinger,
LLC).
2.3. Homology modeling
We used the SWISS-MODEL server [15] and Yasara [16] to cre-
ate homology models of NM-2A in the rigor-like and pre-power
stroke state using our current structure and the pre-power stroke
NM-2C structure (PDB ID: 2YCU) as templates.
3. Results and discussion
3.1. Puriﬁcation and structure determination
The motor domain of human NM-2B0 fused to an a-actinin
lever arm was produced in baculovirus-infected Sf9 cells and puri-
ﬁed to homogeneity by Ni2+-afﬁnity chromatography followed by
gel ﬁltration. Typical yields of 2 mg per liter of cells (106 cells/
mL) were obtained. Plate-shaped crystals belonging to the primi-
tive monoclinic space group P21 grew overnight in 10% (w/v)
PEG-6000 and 0.1 M HEPES pH 7.0 at 18 C (Fig. 1A). The structure
of the NM-2B0 motor domain was determined by molecular
replacement using the nucleotide-free myosin-5A motor domain
structure [12] as a search model (39% sequence identity in the
motor domain, PDB ID: 1OE9). The asymmetric unit contained
two molecules with clearly interpretable electron density for both
molecules, starting from NM-2B0 residues 32 and 33 at the N-ter-
minus and including both a-actinin repeats (Fig. 1B). The model
was reﬁned to a resolution of 2.84 Å, an Rwork of 25.33, and an Rfree
of 28.81 with good geometry (see Table 1 for additional data
collection and reﬁnement statistics). Both molecules are highly
similar (rmsd: 0.629 Å across the whole molecule; 0.382 Å in the
motor domain). Differences are mostly restricted to the a-actinin
lever arm (Fig. 1C).
For both molecules, additional electron density that is clearly
interpretable as protein backbone and side chain density was
observed close to their respective helices A and B. For molecule
A, this stretch was modeled as the N-terminus from amino acids
8 to 21, whereas for molecule B it was modeled as residues 9–20.
Residues 8–21 extend across the lever arm to the opposite side
of the motor domain, where they contact the loop that follows
helix A (residues 111–114) and the loop regions next to helix B
(Fig. 2A and B). These contacts involve a number of hydrophobic
interactions with the motor domain. Residues 1–8 and 22–32 are
not resolved in our electron density map. Residue 33 is located at
the start of the SH3-like subdomain. In the previously determined
nucleotide-free myosin structures of murine myosin-1b and Dd
myosin-2 the N-terminal residues are located in a similar position
[17,18] (Fig. 2B). In the Dd myosin-2 structure, the residues
connecting the SH3 subdomain to the N-terminal stretch are
well-resolved.
In comparison with previously determined myosin structures in
the nucleotide-free state, chicken myosin-5A is the most similar
with an rmsd of 0.98 Å in the motor domain. Despite this
Fig. 3. Differences to other myosin structures determined in the nucleotide-free state. The motor domains of Dd myosin-2 (PDB ID: 2AKA, shown in green) and chicken
myosin-5A (PDB ID: 1OE9, shown in red) have been structurally aligned with our NM-2B structure (shown in blue) to their lower 50kDa domains. (A) Close-up view of the
structural alignment of NM-2B and myosin-5A in the region around the N-terminal tip of helix O shows a different orientation of this helix compared to myosin-5A as
denoted by pink bars. (B) Close-up view of the same alignment as in (A) around the central b-sheet, which is highly distorted in the nucleotide-free state. The black arrow
denotes a different orientation of the 7th strand in NM-2B as compared to myosin-5A. Due to the different conformation of the 7th strand, the b-sheet is less distorted in NM-
2B as compared to myosin-5A. (C) Comparison of the actin-binding region around loop 3 of different myosins (NM-2B, myosin-5A and Dd myosin-2) in the nucleotide-free
state. Note the different orientation and length of NM-2B’s loop 3 as compared to myosin-5A and Dd myosin-2. A sequence alignment of these myosin’s loop 3 regions
illustrates the elongation of loop 3 of NM-2B. (D) Comparison of the active site elements switch I, switch II and P-loop of nucleotide-free NM-2B, myosin-5A and Ddmyosin-2.
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have an impact on the functional properties of these motors. When
structurally aligning the lower 50kDa domain of myosin-5A with
our NM-2B0 structure, the N-terminal tip of helix O is shifted 3 Å
towards the center of the large cleft that divides the upper and
lower 50kDa domains of the myosin motor (Fig. 3A). As a result,
the large cleft of NM-2B0 is more closed when compared with
myosin-5A (as denoted by pink bars in Fig. 3A). Moreover, the
7th strand of the NM-2B0 central b-sheet shows approximately
10 less twisting (Fig. 3B).
Structural models of the actin-myosin interface show that
myosin interacts with two adjacent actin molecules. Loop 2, helixW, loop 4, and the CM loop of myosin form large contacts to SD1
and SD3 of the neighboring actin molecule. A helix-loop-helix
motif of the lower 50kDa subdomain of myosin protrudes into a
cavity formed by SD1 and SD3 of the upper and by the SD2 domain
of next lower actin along the long pitch helix, thereby interacting
with both of them. In addition, myosins with an extended loop 3
carrying a net positive charge can form a contact with SD1 of the
lower actin monomer in the ﬁlament [19,20]. In comparison to
both Dd myosin-2 (PDB ID: 2AKA) and chicken myosin-5A (PDB
ID: 1OE9) loop 3 is elongated and assumes a different conforma-
tion (see Fig. 3C). NM-2B and myosin-5A share a net charge of
+2, while loop 3 of Dd myosin-2 has a net charge of 1. Therefore,
Fig. 4. Chemical environment of the disease-related residue R709 in the NM-2B motor domain. The overview shows the location of the mutated amino acid R709 that is
implicated in MYH9-RD. The relay helix is highlighted blue, whereas the SH1/SH2 helices are colored green. The box shows a close-up view of the chemical environment of
R709, which is mutated to cysteine or histidine in MYH9-RD. The orientation in the close-up view has been turned by about 45 for better visibility.
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tional salt-bridge in the interaction with actin contributes to the
deﬁnition of the functional properties of NM-2B.
The active site geometry is similar to that of myosin-5A, but sig-
niﬁcantly different to Dd myosin-2 (Fig. 3D). The most prominent
difference to Dd myosin-2 that myosin-5A and NM-2B0 share is a
different conformation of the P-loop. When aligning these three
myosins to their respective lower 50kDa domains, the P-loops of
Dd myosin-2 and NM-2B0 are 4 Å apart from each other, such that
the active site of NM-2B0 is more closed (Fig. 3D). Nucleotide bind-
ing and release kinetics of NM-2B are ﬁne-tuned by changes in
loop 1 (S.P-C., S.M. and D.J.M., unpublished results). Loop 1 is
extended in neuronal splice isoforms of the protein. Electron den-
sity for loop 1 is weak in our structure, suggesting that this region
is highly ﬂexible. Changes in the length of loop 1 are thought to
have an effect on the torsional ﬂexibility of the 7-stranded central
b-sheet of the motor domain, thereby affecting mechanochemical
coupling [12,17,21]. Studies performed with other myosin isoforms
revealed effects on the kinetic properties of the myosin motor
domain associated with changes in the length of loop 1 [22]. In
the case of Myo1c [23], the recently reported pre-power stroke
state structure revealed a well ordered loop 1, which is in close
proximity to the calmodulin bound to IQ1 of the lever arm [24].3.2. Structural implications for MYH9-RD mutations
Mutations W37C, A99D, N97K, S100L and R725W (NM-2B0
numbering) cluster close to the base of the lever arm at the inter-
face between the N-terminal SH3-like b-barrel and the motor
domain. These mutations are likely to affect the communication
pathway between the light chain binding domain and the motor
domain. Since our structure lacks the native light chain binding
domain, we cannot comment on the exact nature of the resulting
perturbations and whether they primarily affect the mechanical
stiffness of the region or interfere with the activation of the motor
following phosphorylation of the regulatory light chain. The
situation is more favorable in regard to mutations that lead to
the replacement of residue R709. A structural alignment of our
NM-2B0 motor domain structure with a homology model of the
NM-2A motor domain shows the location of the MYH9-RD muta-
tions R709C and R709H (Fig. S1A). Mutations at this position affect
an interface that is located well within the motor domain involving
residues from the SH1/SH2 and relay regions. The region under-
goes large conformational changes during the ATPase cycle and is
of central importance for the coupling between the active site
and the lever arm region. A sequence alignment of the regions
around R709 shows the near identity of NM-2A and NM-2B
S. Münnich et al. / FEBS Letters 588 (2014) 4754–4760 4759sequence in this part of the motor domain (Fig. S1B). The alignment
also shows the 7 amino acids offset in the sequence register of
NM-2A compared to the non-inserted NM-2B splice isoform B0,
such that R709 corresponds to R702 in NM-2A.
Previous studies assessed the effects of MYH9-RD mutation
R709C by characterizing the functional behavior of recombinant
mutant constructs [9,25,26]. The crystal structures of chicken
smooth muscle myosin in complex with bound ADP-AlF4 (PDB
ID: 1BR1) or Dd myosin-2 complex with MgADP (PDB ID: 1G8X)
were used to interpret the observed functional changes as a conse-
quence of a destabilization of the SH1 helix brought about by the
disruption of a stabilizing interaction between R709 and Q713
[27,28].
With our structure of NM-2B in the rigor-like state and a
homology model based on the pre-power stroke state structure
of the NM-2C motor domain (PDB ID: 2YCU), we aimed to reeval-
uate the effects of mutations R709C and R709H. In the rigor-like
structure, R709 forms salt-bridges with E706 in the SH1 helix
and D514, which is located at the start of the helix that follows
after the relay loop (Fig. 4). These salt bridges form part of a larger
interaction network. Further stabilizing interactions of this net-
work include hydrophobic contacts between I710 of the SH1 helix
and F511, as well as hydrogen bonds between Q484 and N488 of
the relay helix with E706 of the SH1 helix and N702 of the SH2
helix.
The interactions of R709 that are predicted to occur in the
pre-power stroke state are different from those observed in our
rigor-like structure. Due to a rotation of the SH1 helix, R709 points
in the opposite direction, where it interacts with the peptide car-
bonyl function of L96, which is located at the interface between
the SH3-like subdomain and the core of the motor domain
(Fig. S2). The interface between the SH1/relay helix and relay loop
is largely dominated by a hydrophobic interaction network includ-
ing residues I710 of the SH1 helix, L513, F511, I509 and F508 of the
relay loop and the helix that follows the relay loop and F492 and
I493 of the relay helix (Fig. S2). In the nucleotide-free state, both
mutations R709C and R709H disrupt the interactions that R709
participates in, thereby interfering with coupling between the
nucleotide binding site and the lever arm. Coupling between the
nucleotide- and actin-binding sites and actin-activated turnover
of ATP are predicted to be affected to a lesser extent. These conclu-
sions are in good agreement with previously described functional
changes. These include the complete loss of the mutant protein’s
ability to move actin ﬁlaments in an in vitro motility assay, while
the rate of actin-activated ATP turnover is reduced only 3-fold
for the R709C mutant [29]. Our conclusions about the interaction
network around R709 are in line with predictions made by a recent
study that used homology models of NM-2A based on structures of
other class-2 myosins [30].Accession numbers
The coordinates and structure factors of nucleotide-free human
NM-2B have been deposited in the Protein Data Bank under the
accession code 4PD3.Acknowledgements
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